On December 6, MEDIPOST announced that it has obtained a patent for its stem cell-based composition for the treatment of cartilage injury in 6 European countries including UK, Germany, France, Italy, Spain and Switzerland.
The title of this patent is ‘TSP-1, TSP-2, IL-17BR and HB-EGF associated with stem cell activities and applications thereof’.
This technology was developed for treatment and prevention of cartilage injury, degeneration, loss as well as of degenerative arthritis.
MEDIPOST already had obtained a similar patent in the same European countries in 2015.
MEDIPOST expects that it will be able to use these two patents for manufacturing its degenerative arthritis treatment drug ‘CARTISTEM’ in Europe in the future.